Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of RC28-E vs Aflibercept in Diabetic Macular Edema
NCT05885503Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of eflimrufusp alfa in diabetic macular edema (DME), sponsored by RemeGen. Started Jun 2023; status: recruiting.
02
Drugs
eflimrufusp alfa
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05885503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885503.